TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Down 56.6% in June

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 24,900 shares, a decline of 56.6% from the May 31st total of 57,400 shares. Based on an average daily trading volume, of 2,310,000 shares, the days-to-cover ratio is presently 0.0 days.

TC Biopharm Trading Down 1.2 %

TCBP stock traded down $0.01 during midday trading on Friday, reaching $0.82. The stock had a trading volume of 79,738 shares, compared to its average volume of 2,843,157. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.88 and a quick ratio of 0.88. The business has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $1.58. TC Biopharm has a twelve month low of $0.72 and a twelve month high of $19.60.

TC Biopharm (NASDAQ:TCBP) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($2.80) earnings per share for the quarter.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.